Novo Nordisk A/S (NONOF)

USD 61.92

(-1.26%)

Market Cap (In USD)

274.86 Billion

Revenue (In USD)

232.26 Billion

Net Income (In USD)

83.68 Billion

Avg. Volume

93.52 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
98.03-149.55
PE
18.48
EPS
3.35
Beta Value
0.165
ISIN
DK0062498333
CUSIP
-
CIK
353278
Shares
4439052539.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lars Fruergaard Jorgensen
Employee Count
-
Website
https://www.novonordisk.com
Ipo Date
2010-05-07
Details
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.